A detailed history of Jpmorgan Chase & CO transactions in Uni Qure N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 665,580 shares of QURE stock, worth $4.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
665,580
Previous 969,504 31.35%
Holding current value
$4.27 Million
Previous $5.04 Million 40.86%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$4.39 - $5.43 $1.33 Million - $1.65 Million
-303,924 Reduced 31.35%
665,580 $2.98 Million
Q1 2024

May 10, 2024

BUY
$4.82 - $6.93 $1.06 Million - $1.53 Million
220,150 Added 29.38%
969,504 $5.04 Million
Q4 2023

Feb 12, 2024

BUY
$5.63 - $8.27 $880,717 - $1.29 Million
156,433 Added 26.38%
749,354 $5.07 Million
Q3 2023

Nov 14, 2023

SELL
$6.71 - $11.83 $177,372 - $312,714
-26,434 Reduced 4.27%
592,921 $3.98 Million
Q2 2023

Aug 11, 2023

SELL
$11.12 - $22.2 $1.33 Million - $2.65 Million
-119,359 Reduced 16.16%
619,355 $7.1 Million
Q1 2023

May 11, 2023

BUY
$18.7 - $23.07 $1.26 Million - $1.56 Million
67,409 Added 10.04%
738,714 $14.9 Million
Q4 2022

Feb 13, 2023

SELL
$18.12 - $27.32 $1.12 Million - $1.7 Million
-62,055 Reduced 8.46%
671,305 $15.2 Million
Q3 2022

Nov 14, 2022

SELL
$16.98 - $25.54 $1.19 Million - $1.8 Million
-70,309 Reduced 8.75%
733,360 $13.8 Million
Q2 2022

Aug 11, 2022

SELL
$13.15 - $20.45 $1.07 Million - $1.66 Million
-81,151 Reduced 9.17%
803,669 $15 Million
Q1 2022

May 11, 2022

BUY
$14.54 - $21.5 $2.53 Million - $3.74 Million
174,069 Added 24.49%
884,820 $16 Million
Q4 2021

Feb 10, 2022

SELL
$20.24 - $36.01 $158,742 - $282,426
-7,843 Reduced 1.09%
710,751 $14.7 Million
Q3 2021

Nov 12, 2021

BUY
$26.01 - $38.22 $18.7 Million - $27.5 Million
718,594 New
718,594 $23 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.